Thymosin in the treatment of HBeAg-negative chronic hepatitis B.

@article{Saru2003ThymosinIT,
  title={Thymosin in the treatment of HBeAg-negative chronic hepatitis B.},
  author={Murat Saruç and Nuri Ozden and Hakan Yuceyar},
  journal={Medical science monitor : international medical journal of experimental and clinical research},
  year={2003},
  volume={9 8},
  pages={RA198-202}
}
Chronic hepatitis B virus (HBV) infection, which can lead to cirrhosis and hepatocellular carcinoma, is a major health threat worldwide. Classic patients with chronic hepatitis B are positive for hepatitis Be-antigen (HBeAg) and HBV-DNA. In the Mediterranean basin, 30-80% of patients with chronic hepatitis B (CHB) are HBeAg-negative, in contrast to Northern European countries and the US, where only 10-40% of CHB patients are lacking HbeAg. HBeAg-negative CHB usually runs a progressive course… CONTINUE READING